Partnering to Expand Therapeutic Boundaries

Exelixis has established multiple partnerships and collaborations with other leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of potential therapies for cancer and other serious diseases.

Esaxerenone (CS-3150)

Esaxerenone (CS-3150) is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. MR blockers can be used to treat hypertension and congestive heart failure due to their vascular protective effects. Recent studies have also shown beneficial effects of adding MR blockers to the treatment regimen for patients with type 2 diabetes with nephropathy. As a non-steroidal, selective MR antagonist, esaxerenone may have the potential for the treatment of hypertension and congestive heart failure, and may provide protection from end organ damage due to vascular complications.

Esaxerenone is one of the compounds identified during Exelixis’ research collaboration with Daiichi Sankyo, which the companies entered into in March 2006. Under the terms of the agreement, Exelixis granted Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR. In exchange, Exelixis received a $20 million upfront payment, research funding for a joint research period, and the potential for clinical development, regulatory and commercialization milestone payments, as well as double-digit royalties on sales. Since the conclusion of the joint research period in November 2007, Daiichi Sankyo has been responsible for all subsequent preclinical and clinical development, and will also oversee regulatory, manufacturing and commercialization activities for the compound.

Following the announcement of positive data from the ESAX-HTN phase 3 pivotal trial, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone as a treatment for patients with hypertension in January 2019. Daiichi Sankyo markets esaxerenone as MINNEBRO® for this indication in Japan. In November 2019, Daiichi Sankyo announced positive results from ESAX-DN, a phase 3 pivotal trial of esaxerenone in patients with diabetic nephropathy. Additional clinical development work is ongoing; for more information on the esaxerenone clinical trial program, please visit

ROR Antagonists

RORs are members of the nuclear hormone receptor family and consist of three related family members, RORα, β, and γ. An isoform of RORγ, known as RORγ-t, is required for the development and function of a subset of T-lymphocytes called TH17 cells. These cells secrete pro-inflammatory cytokines such as IL-17 and IL-23 and are thought to be associated with a variety of inflammatory conditions including psoriasis and multiple sclerosis. Small molecule antagonists of RORγ may block TH17 cell development and function and thereby serve as anti-inflammatory agents. In October 2010, Exelixis entered into a joint discovery program with Bristol Myers Squibb to optimize and characterize RORγ antagonists. Since the end of the collaborative research period in July 2013, Bristol-Myers Squibb has had and will continue to have sole responsibility for further research, development, manufacture, and commercialization of products developed under the collaboration.

Clinical Trials

Our lead medicines are involved in a broad clinical trial development program.